Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT) and Community Health (CYH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Summit Therapeutics (SMMT – Research Report) and Community Health (CYH – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Summit Therapeutics (SMMT)
In a report released yesterday, Etzer Darout from Barclays maintained a Hold rating on Summit Therapeutics, with a price target of $18.00. The company’s shares closed last Monday at $16.09.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Summit Therapeutics with a $57.98 average price target.
See today’s best-performing stocks on TipRanks >>
Community Health (CYH)
Raymond James analyst John Ransom maintained a Sell rating on Community Health yesterday. The company’s shares closed last Monday at $3.33.
Ransom has an average return of
According to TipRanks.com, Ransom is ranked #1005 out of 12109 analysts.
Currently, the analyst consensus on Community Health is a Hold with an average price target of $3.70, representing a 3.9% upside. In a report issued on February 19, Wells Fargo also maintained a Sell rating on the stock with a $2.00 price target.
